322 related articles for article (PubMed ID: 30261105)
1. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
[TBL] [Abstract][Full Text] [Related]
2. Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment.
Zhang XF; Beal EW; Chakedis J; Lv Y; Bagante F; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Weiss M; Pawlik TM
J Gastrointest Surg; 2017 Nov; 21(11):1821-1830. PubMed ID: 28730354
[TBL] [Abstract][Full Text] [Related]
3. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis.
Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Feb; 117(2):171-181. PubMed ID: 28940257
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study.
Sham JG; Ejaz A; Gage MM; Bagante F; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss MJ; Marques HP; Aldrighetti L; Pawlik TM; He J
J Gastrointest Surg; 2019 Mar; 23(3):484-491. PubMed ID: 29980977
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.
Spolverato G; Bagante F; Aldrighetti L; Poultsides G; Bauer TW; Field RC; Marques HP; Weiss M; Maithel SK; Pawlik TM
J Gastrointest Surg; 2017 Dec; 21(12):2039-2047. PubMed ID: 28744737
[TBL] [Abstract][Full Text] [Related]
6. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?
Xiang JX; Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
Ann Surg Oncol; 2018 Dec; 25(13):3928-3935. PubMed ID: 30218247
[TBL] [Abstract][Full Text] [Related]
7. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multi-institutional analysis.
Spolverato G; Bagante F; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Weiss M; Pawlik TM
J Surg Oncol; 2017 Sep; 116(3):298-306. PubMed ID: 28513896
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine liver metastasis: The chance to be cured after liver surgery.
Bagante F; Spolverato G; Merath K; Postlewait LM; Poultsides GA; Mullen MG; Bauer TW; Fields RC; Lamelas J; Marques HP; Aldrighetti L; Tran T; Maithel SK; Pawlik TM
J Surg Oncol; 2017 May; 115(6):687-695. PubMed ID: 28146608
[TBL] [Abstract][Full Text] [Related]
9. Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium.
Zhang XF; Beal EW; Chakedis J; Chen Q; Lv Y; Ethun CG; Salem A; Weber SM; Tran T; Poultsides G; Son AY; Hatzaras I; Jin L; Fields RC; Buettner S; Scoggins C; Martin RCG; Isom CA; Idrees K; Mogal HD; Shen P; Maithel SK; Schmidt CR; Pawlik TM
World J Surg; 2018 Sep; 42(9):2919-2929. PubMed ID: 29404753
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis.
Ejaz A; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss MJ; Marques HP; Aldrighetti L; Pawlik TM
HPB (Oxford); 2018 Mar; 20(3):277-284. PubMed ID: 28964630
[TBL] [Abstract][Full Text] [Related]
11. Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation.
Ruzzenente A; Bagante F; Bertuzzo F; Aldrighetti L; Campagnaro T; Ercolani G; Conci S; Giuliante F; Dore A; Ferrero A; Torzilli G; Grazi GL; Ratti F; Cucchetti A; De Rose AM; Russolillo N; Cimino M; Perri P; Guglielmi A; Iacono C
J Gastrointest Surg; 2019 Jan; 23(1):93-100. PubMed ID: 30242647
[TBL] [Abstract][Full Text] [Related]
12. Conditional disease-free survival after curative-intent liver resection for neuroendocrine liver metastasis.
Sahara K; Merath K; Tsilimigras DI; Hyer JM; Guglielmi A; Aldrighetti L; Weiss M; Fields RC; Poultsides GA; Maithel SK; Endo I; Pawlik TM; Other Members Of The U S Neuroendocrine Tumor Study Group
J Surg Oncol; 2019 Dec; 120(7):1087-1095. PubMed ID: 31550406
[TBL] [Abstract][Full Text] [Related]
13. Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database.
Fairweather M; Swanson R; Wang J; Brais LK; Dutton T; Kulke MH; Clancy TE
Ann Surg Oncol; 2017 Aug; 24(8):2319-2325. PubMed ID: 28303430
[TBL] [Abstract][Full Text] [Related]
14. Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis.
Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
Ann Surg Oncol; 2020 Oct; 27(10):3717-3726. PubMed ID: 32436187
[TBL] [Abstract][Full Text] [Related]
15. Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma.
Hu LS; Zhang XF; Weiss M; Popescu I; Marques HP; Aldrighetti L; Maithel SK; Pulitano C; Bauer TW; Shen F; Poultsides GA; Soubrane O; Martel G; Koerkamp BG; Itaru E; Pawlik TM
Ann Surg Oncol; 2019 Aug; 26(8):2549-2557. PubMed ID: 31020501
[TBL] [Abstract][Full Text] [Related]
16. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.
Mayo SC; de Jong MC; Bloomston M; Pulitano C; Clary BM; Reddy SK; Clark Gamblin T; Celinski SA; Kooby DA; Staley CA; Stokes JB; Chu CK; Arrese D; Ferrero A; Schulick RD; Choti MA; Geschwind JF; Strub J; Bauer TW; Adams RB; Aldrighetti L; Mentha G; Capussotti L; Pawlik TM
Ann Surg Oncol; 2011 Dec; 18(13):3657-65. PubMed ID: 21681380
[TBL] [Abstract][Full Text] [Related]
17. Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group.
Zhang XF; Wu Z; Cloyd J; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Cho C; Beems M; Schmidt CR; Dillhoff M; Maithel SK; Pawlik TM
Surgery; 2019 Mar; 165(3):548-556. PubMed ID: 30278986
[TBL] [Abstract][Full Text] [Related]
18. Early Versus Late Recurrence of Hepatocellular Carcinoma After Surgical Resection Based on Post-recurrence Survival: an International Multi-institutional Analysis.
Wei T; Zhang XF; Bagante F; Ratti F; Marques HP; Silva S; Soubrane O; Lam V; Poultsides GA; Popescu I; Grigorie R; Alexandrescu S; Martel G; Workneh A; Guglielmi A; Hugh T; Lv Y; Aldrighetti L; Pawlik TM
J Gastrointest Surg; 2021 Jan; 25(1):125-133. PubMed ID: 32128681
[TBL] [Abstract][Full Text] [Related]
19. Repeat hepatectomy for patients with recurrent neuroendocrine liver metastasis: Comparison with first hepatectomy.
Kiritani S; Arita J; Matsumura M; Nishioka Y; Kudo H; Ichida A; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
Surgery; 2020 Feb; 167(2):404-409. PubMed ID: 31635827
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy.
Postlewait LM; Ethun CG; Baptiste GG; Le N; McInnis MR; Cardona K; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK
J Surg Oncol; 2016 Sep; 114(4):440-5. PubMed ID: 27334541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
